The endometriosis treatment protocol provides for administering to a
female patient in need of treatment for endometriosis a pharmaceutical
composition in a form suitable for vaginal or rectal delivery having a
pharmaceutically effective amount of an aromatase inhibitor, which may be
either a steroid or non-steroidal. The pharmaceutical composition may be
formed as a vaginal suppository, a rectal suppository, a vaginal gel, a
rectal gel, a vaginal cream or a rectal cream. The pharmaceutical
composition may optionally have pharmaceutically effective amounts of
progesterone and calcitriol, and may be administered in combination with
an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition
comprises an aromatase inhibitor administered vaginally or rectally and
is administered in combination with oral calcitriol and the oral COX-2
inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.
